A Rapid LC-MS/MS-PRM Assay for Serologic Quantification of Sialylated O-HPX Glycoforms in Patients with Liver Fibrosis.
Aswini PanigrahiJulius BenickyRenhuizi WeiJaeil AhnRadoslav GoldmanMiloslav SandaPublished in: Molecules (Basel, Switzerland) (2022)
Development of high throughput robust methods is a prerequisite for a successful clinical use of LC-MS/MS assays. In earlier studies, we reported that nLC-MS/MS measurement of the O-glycoforms of HPX is an indicator of liver fibrosis. In this study, we show that a microflow LC-MS/MS method using a single column setup for capture of the analytes, desalting, fast gradient elution, and on-line mass spectrometry measurements, is robust, substantially faster, and even more sensitive than our nLC setup. We demonstrate applicability of the workflow on the quantification of the O-HPX glycoforms in unfractionated serum samples of control and liver disease patients. The assay requires microliter volumes of serum samples, and the platform is amenable to one hundred sample injections per day, providing a valuable tool for biomarker validation and screening studies.
Keyphrases
- liver fibrosis
- high throughput
- mass spectrometry
- ms ms
- end stage renal disease
- single cell
- liquid chromatography
- newly diagnosed
- chronic kidney disease
- prognostic factors
- case control
- high resolution
- patient reported outcomes
- electronic health record
- coronavirus disease
- liquid chromatography tandem mass spectrometry
- patient reported
- quantum dots
- simultaneous determination
- solid phase extraction
- tandem mass spectrometry